Clinical study
In a randomized, double blind, parallel group, placebo controlled trial, SesaVita (500 mg/day for a period of 6 weeks) along with therapeutic lifestyle changes treated group showed significant reduction in low density lipoprotein cholesterol (LDL-C) and fasting blood sugar (FBS) levels when compared to placebo in patients with prediabetes and mild to moderate hyperlipidemia.
Clinical study is published in Journal of Food Research (Published by the Canadian Center of Science and Education) 2013 DOI: 10.5539/jfr.v2n5p104. Read More
Effect of SesaVita on LDL-C and FBS levels
Safety data
SesaVita (500 mg/day) showed no adverse effects in patients with prediabetes and mild to moderate hyperlipidemia throughout the study duration. The physical examination and clinical laboratory investigations performed on day 0 and week 6 in SesaVita treated groups were found to be within normal limits.